A review of the clinical characteristics and management of immunosuppressed patients living with HIV or solid organ transplants infected with SARS-CoV-2 omicron variants
- PMID: 38454994
- PMCID: PMC10917969
- DOI: 10.3389/fpubh.2024.1327093
A review of the clinical characteristics and management of immunosuppressed patients living with HIV or solid organ transplants infected with SARS-CoV-2 omicron variants
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) omicron strain was first detected in South Africa in November 2021. Although clinical responses to SARS-CoV-2 depend on host immunity, it remains uncertain how immunosuppression affects subsequent coronavirus disease 2019-related (COVID-19-related) incidence, severity, and mortality, especially with respect to the omicron strain. Conversely, immunosuppressants are often thought to predispose to infection. To explore the associations between host immunity and infection with SARS-CoV-2 omicron variants, here we discuss two groups of immunosuppressed patients: organ transplant recipients, who generally receive exogenous immunosuppressants, and Human Immunodeficiency Virus (HIV)-infected patients, who often have disease-related immunosuppression. In summarizing the clinical features and prognoses of HIV-infected patients and human organ transplant recipients infected with SARS-CoV-2 omicron variants, we provide new insights into the pathogenesis of omicron SARS-CoV-2 and provide a framework for the management of these patients now and in the future.
Keywords: HIV; SARS-CoV-2 infection; immunosuppression; inflammation; omicron; organ transplant.
Copyright © 2024 Song, Lou and Zhang.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Favorable outcomes of COVID-19 in vaccinated hematopoietic stem cell transplant recipients: A single-center experience.Transpl Infect Dis. 2023 Jun;25(3):e14024. doi: 10.1111/tid.14024. Epub 2023 Feb 7. Transpl Infect Dis. 2023. PMID: 36715661
-
COVID-19 Disease in Pediatric Solid Organ Transplantation from Alpha to Omicron: A High Monocyte Count in the Preceding Three Months Portends a Risk for Severe Disease.Viruses. 2023 Jul 16;15(7):1559. doi: 10.3390/v15071559. Viruses. 2023. PMID: 37515245 Free PMC article.
-
Is the Omicron variant truly less virulent in solid organ transplant recipients?Transpl Infect Dis. 2022 Dec;24(6):e13923. doi: 10.1111/tid.13923. Epub 2022 Aug 12. Transpl Infect Dis. 2022. PMID: 35915957 Free PMC article.
-
Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions.Ther Drug Monit. 2020 Jun;42(3):360-368. doi: 10.1097/FTD.0000000000000761. Ther Drug Monit. 2020. PMID: 32304488 Free PMC article. Review.
-
Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities.Heliyon. 2023 Feb;9(2):e13285. doi: 10.1016/j.heliyon.2023.e13285. Epub 2023 Jan 31. Heliyon. 2023. PMID: 36744070 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous